Analytical characterisation of biotherapeutics at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

46 organizations at PEGS Europe 2026 present work in analytical characterisation: 36 suppliers and service providers, 8 drug developers and 2 academic, government and non-profit bodies. Between them they bring 51 presentations to the program. Most represented: iBET (7 on the program), Novartis (6 on the program), Sanofi (4 on the program). As of Oct 8, 2026.

All 541 organizations at PEGS Europe 2026 →

Showing 1–9 of 46 organizations

Organization	PEGS Europe 2026 Attendance
iBET Oeiras, Portugal	◆Corporate Support Sponsor
ibet.pt AcademicCorporate Support Sponsor Portuguese non-profit research institute doing protein production, antibody discovery and bioprocess work, including contract research for industry.	Booth Exhibiting at Booth 123 Tue, Nov 1710:30am–7:50pmWed, Nov 1810:30am–5:30pmThu, Nov 1910:00am–2:00pm Chair Tue Nov 17 8:25am–8:30am Chairperson's Welcome Remarks Leveraging Data Science for Enhanced Protein Expression Talk Tue Nov 17 5:20pm–5:50pm The Development of iSeRa-AI, a Tool for Automatic Selection of mAbs from Antibody Display Coupled to Deep Sequencing Display of Biologics Talk Tue Nov 17 5:50pm–6:20pm 3D Tumour Microenvironments Enable Mechanistic Profiling of ADCs and Immunomodulatory Antibodies Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Wed Nov 18 11:15am–11:45am Integrating Genome-Wide CRISPR Screening and Host Cell Engineering in HeLaS3 Producer Lines for rAAV Production Designing High-Performance Expression Platforms Talk Wed Nov 18 7:00pm–7:30pm Decoding Macrophage-Fibroblast Cross-Talk to Enable Next-Generation Anti-Fibrotic Therapies Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 8:30am–9:00am Advanced Bioanalytics for Comprehensive Characterisation of Biotherapeutics Manufacturing Highly Parallel Protein Discovery Workflows Panel Thu Nov 19 5:05pm–5:45pm Higher-Throughput Biopharmaceutical Workflow Challenges Highly Parallel Protein Discovery Workflows · with University of Surrey, University College London, Septerna +1 more
Novartis Basel, Switzerland
novartis.com Large pharma Swiss pharmaceutical company with a large biologics pipeline across oncology, immunology, cardiovascular and neuroscience.	Talk Tue Nov 17 9:30am–10:00am In silico Approaches for siRNA AOC Optimisation Optimisation & Developability Chair Tue Nov 17 2:00pm–2:05pm Chairperson's Remarks Optimisation & Developability Chair Wed Nov 18 8:25am–8:30am Chairperson's Remarks Analytical Characterisation of Biotherapeutics Talk Wed Nov 18 9:00am–9:30am From Suspension to Signal: Enabling Analytical Characterisation of Therapeutic Proteins in High-Dose Non-Aqueous Suspension Formulations Analytical Characterisation of Biotherapeutics Talk Wed Nov 18 6:00pm–6:30pm Design of Potency Assays in Development of Standard and Complex Biologics Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 8:30am–9:00am Mechanistic Understanding of an Unusually Stable Succinimide Intermediate in an Antibody Therapeutic Protein Stability & Formulation Chair Thu Nov 19 2:00pm–2:05pm Chairperson's Remarks Protein Stability & Formulation Panel Thu Nov 19 3:35pm–4:15pm High-Dose Options for the Diverse Biologics Modalities and the Unknowns Protein Stability & Formulation
Sanofi Paris, France
sanofi.com Large pharma French pharmaceutical company developing antibodies, Nanobody molecules, multispecifics and other biologics across immunology, oncology and rare diseases.	Talk Wed Nov 18 9:30am–10:00am Structural Biology at the Forefront of Biotherapeutics: Cryo-EM, AI, and Complex Modalities Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 9:00am–9:30am Colloidal Stability Prediction of Multivalent NANOBODY Molecules Using Machine Learning Protein Stability & Formulation Chair Thu Nov 19 10:44am–10:45am Chairperson's Remarks Machine Learning for Protein Engineering Part 2 Talk Thu Nov 19 11:05am–11:25am De novo VHH Design in Practice: Bridging AI Innovation with Real-World Biologics Design Machine Learning for Protein Engineering Part 2 Talk Thu Nov 19 5:15pm–5:45pm Precision-Activated T Cell Engagers in Immuno-Oncology: Pharmacological Characterisation of Albumin-Masked TCR Multispecific VHHs Engineering the Next Generation of Bispecific Antibodies
Genentech South San Francisco, CA
gene.com Large pharma Roche group biotechnology company discovering and developing antibody and protein medicines in oncology, immunology and other areas.	Talk Tue Nov 17 11:45am–12:15pm Multi-Objective Antibody Optimisation with Property Enhancer (PropEn) Optimisation & Developability Talk Wed Nov 18 2:05pm–2:35pm AI-Based Analysis of Label-Free Live Cell Imaging of T Cell Mediated Tumour Killing Assay Enables Competitive and Robust Hit Calling Analytical Characterisation of Biotherapeutics Talk Wed Nov 18 6:30pm–7:00pm SMACk: A Modular Platform for Sterically Masked Activated Cytokines Biologics for Autoimmune Diseases Talk Thu Nov 19 2:35pm–3:05pm Comparative Analysis of 4-1BB and CD28 Tumour-Targeted Co-Stimulation to Support T Cell Bispecific Antibody Therapy in Solid Tumours Engineering the Next Generation of Bispecific Antibodies
Novo Nordisk Bagsværd, Denmark
novonordisk.com Large pharma Danish pharmaceutical company known for diabetes and obesity medicines, with in-house protein and peptide drug discovery.	Talk Tue Nov 17 9:00am–9:30am IVTT-Accelerated Protein Discovery: Generating Fit-for-Purpose AI Training Data Leveraging Data Science for Enhanced Protein Expression Talk Wed Nov 18 6:30pm–7:00pm High-Throughput Automation Platform for Miniaturised Biophysical Assays: Accelerating Compound Screening with One Click Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 8:50am–9:10am Long Acting, Stable Urocortin-2 Analogues for the Treatment of Obesity and Diabetes Novel Peptide Drug Discovery Talk Thu Nov 19 2:05pm–2:35pm Real-World Progress, Challenges, and Opportunities for AI in Protein and Peptide Discovery Novel Peptide Drug Discovery
Chugai Pharmaceutical Tokyo, Japan
chugai-pharm.co.jp Large pharma Japanese pharmaceutical company in the Roche group, known for antibody engineering technologies such as recycling and bispecific antibodies.	Talk Wed Nov 18 8:30am–9:00am Empowering Next-Generation Antibodies: Synergy of Conditional Activation and Fc Engineering Engineering Antibodies & Beyond Talk Wed Nov 18 8:30am–9:00am Strategy for Evaluating Undesired Mis-Paired Variants across Bispecific Antibody Modalities Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 2:35pm–3:05pm Molecular Dynamics Analysis toward Understanding Formulation-Dependent DSC Behaviour of Antibodies Protein Stability & Formulation
Boehringer Ingelheim Ingelheim am Rhein, Germany
boehringer-ingelheim.com Large pharma Family-owned pharmaceutical company with human and animal health businesses and large biologics development and contract manufacturing operations.	Talk Wed Nov 18 11:45am–12:15pm Thermal Unfolding: From Heuristic Interpretation to Quantitative Models Analytical Characterisation of Biotherapeutics Chair Thu Nov 19 8:25am–8:30am Chairperson's Remarks Protein Stability & Formulation Talk Thu Nov 19 2:05pm–2:35pm What Have We Learned from a Decade of Research into Polysorbate Degradation? Protein Stability & Formulation
FyoniBio Berlin, Germany	◆Corporate Sponsor
fyonibio.com CRO & CDMOCorporate Sponsor Berlin CDMO offering CHO cell line and bioprocess development, glycoengineering know-how and bioanalytical services for biologics.	Booth Exhibiting at Booth 114 Tue, Nov 1710:30am–7:50pmWed, Nov 1810:30am–5:30pmThu, Nov 1910:00am–2:00pm Talk Wed Nov 18 10:15am–10:30am Talk Title to be Announced Designing High-Performance Expression Platforms
Abselion	◆Corporate Sponsor
abselion.com Instruments & analyticsCorporate Sponsor Makes the Amperial instrument for measuring protein concentration directly in crude samples during expression and purification.	Booth Exhibiting at Booth 236 Tue, Nov 1710:30am–7:50pmWed, Nov 1810:30am–5:30pmThu, Nov 1910:00am–2:00pm Talk Tue Nov 17 12:15pm–12:45pm Evaluating Alternative Approaches for His-tagged Protein Quantification from Crude Samples: Informing Purification Decisions in Real-time Optimisation & Developability